Prostatectomy, pharmacare, and protein mutations
This week: prostatectomy, prescription drug costs, exome sequencing for rare mutations
Learning objectives – Amol, Nathan, and Travis discuss:
1. Understand that radical prostatectomy improved overall and disease free survival and decreased metastasis compared with watchful waiting in men with localized prostate cancer of intermediate grade.
2. Understand how the cost of prescription drugs is regulated in Canada and how this impacts patients
3. Understand the application of exome sequencing to genetic discovery in rare clinical syndromes
Continuing medical education
Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.
The Rounds Table is a free-flowing conversation and we may mis-speak (or just plain be wrong) from time to time. We will do our best to catch mistakes and where possible, we will edit the episode to correct the error. We will indicate here if any change has been made. If you notice anything, please let us know!
In the original recording, Amol made reference to spending on drugs being 70% public and 30% private. This was an error – 70/30 is the public/private split for overall health care spending in Canada. The correct distribution of drug spending in Canada is 46.5% public, 36% private insurance, and 17.5% out-of-pocket. Reference: CIHI, Drug Expenditures in Canada 1985-2010, table 1, page 10.). The podcast has been edited to reflect the accurate numbers.
Question of the week
Should Canada have a national drug plan?